Multicenter, Real‐World Clinical Evaluation of Alemtuzumab and Anti‐Thymocyte Globulin for Severe Acute T Cell‐Mediated Kidney Transplant Rejection
Mostly, severe TCMRs have good long-term graft survival and function after either alemtuzumab or rATG therapy. No significant differences between the two therapies were found in this real-world clinical experience. Alemtuzumab is an effective alternative to rATG for the treatment of severe TCMR.
Authors
- Dennis A. Hesselink (ORCID: https://orcid.org/0000-0003-1871-1962)
- Marieke van der Zwan (ORCID: https://orcid.org/0000-0002-9404-6135)
- Erzsi Tegzess (ORCID: https://orcid.org/0000-0003-3049-1990)
- Marlies E. J. Reinders (ORCID: https://orcid.org/0000-0001-9543-567X)
- Marian C. Clahsen‐van Groningen (ORCID: https://orcid.org/0000-0003-0565-9560)
- Stefan P. Berger (ORCID: https://orcid.org/0000-0003-2228-4676)
- Jan‐Stephan Sanders (ORCID: https://orcid.org/0000-0002-0904-3969)
- Priya Vart (ORCID: https://orcid.org/0000-0001-5576-820X)
- Brenda C. M. de Winter (ORCID: https://orcid.org/0000-0002-4452-8443)
- Lukas K. van Vugt (ORCID: https://orcid.org/0000-0001-7343-0130)
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- Erasmus MC (NL)
- Albert Schweitzer Ziekenhuis (NL)
- Erasmus MC Cancer Institute (NL)
- Erasmus MC Transplant Institute
- RWTH Aachen University (DE)
Publication Details
- Journal
- Clinical Transplantation
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1111/ctr.70046
- Citations
- 3
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.52